FDA Suggests Gene Therapy Data for Huntington Disease Could Support Accelerated Approval

The FDA has indicated that three-year data from the AMT-130 gene therapy program for Huntington disease may form the basis for an accelerated approval submission. Developer uniQure plans to submit the Biologics License Application in Q3 2026. The agency also proposed a confirmatory study against standard-of-care, potentially avoiding a sham procedure.